Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06376045
Status:
RECRUITING
Last Update Posted:
2024-07-10
First Post:
2024-04-17
Brief Title:
A Phase 2 Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Phase 2 Randomized Double-blind Placebo-controlled Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None